A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

NCT02975934 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

405

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Rucaparib
DRUG: Abiraterone acetate or Enzalutamide or Docetaxel

Sponsor

pharmaand GmbH

Collaborators

[object Object]